Diabetic Nephropathy.
Conditions
Interventions
Intervention 1: placebo for 4 months. Intervention 2: Raloxifen tablets 60mg/daily for 4 months.
Placebo
Treatment - Drugs
placebo for 4 months
Raloxifen tablets 60mg/daily for 4 months
Sponsors
Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria : confirmed menopause (last period of the patient over the past year and FSH levels is more than 25mu/L, Age less than 70 years, confirmed albuminuria due to DM (ACR> 30mg/gr) Exclusion criteria: History of Treatment with estrogen or SERM in the past six months, a personal history of breast or Genicologic cancer, History of thrombotic disorders, GFR less than 30 mL/min, hypertriglyceridemia over than 400 mg/dl, Active liver disease, intolerance to raloxifene or other Allergic reactions
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albuminuryia. Timepoint: at the begining of the study and 4month after intervention. Method of measurement: Nephelometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile(TG, Cholesterol, HDL-C). Timepoint: at the begining of the study and 4month after intervention. Method of measurement: Enzymatic methods.;Blood pressure. Timepoint: at the begining of the study and 2&4 month after intervention. Method of measurement: standard methods checking for BP.;HbA1c. Timepoint: at the beginning of the study and 4 months after intervention. Method of measurement: lone exchange. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Faranak Sharifi
Zanjan Metabolic Diseases Research Center
Outcome results
None listed